Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 0 5 35 21 versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 0 5 35 21 versus PORTIA 21.
NORTREL 0.5/35-21 vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone inhibits ovulation by suppressing gonadotropin release (LH and FSH) and alters cervical mucus and endometrial receptivity. Ethinyl estradiol provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing ovulation.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
1 tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 0.5 mg norethindrone and 35 mcg ethinyl estradiol.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Norethindrone: terminal half-life approximately 7-8 hours. Ethinyl estradiol: terminal half-life approximately 13-27 hours, mean about 17 hours. Ethinyl estradiol exhibits a longer half-life due to enterohepatic recirculation and extensive tissue distribution.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Norethindrone is primarily excreted renally (approximately 60-80% as metabolites) and approximately 20-40% fecally. Ethinyl estradiol is excreted renally (about 40%) and fecally (about 60%) as glucuronide and sulfate conjugates.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive